Uncategorized
Aura Biosciences Forms Clinical Advisory Board in Ocular Oncology and Strengthens Clinical Team to Prepare for Clinical Development of Lead Program in Ocular Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells, announced today that it has formed a Clinical Advisory Board in Ocular Oncology and bolstered its clinical development team as it prepares to initiate clinical testing of its lead program in Ocular (uveal) Melanoma. Carol Shields, MD, co-Director of the Oncology Service at Wills Eye Hospital of Thomas Jefferson University in Philadelphi
